Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $157.9M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Bicycle Therapeutics PLC as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 99
- −11 vs. Q2 2025
- Shares held
- 36.9M
- −4.29M (−10.4%) vs. Q2 2025
- Total value
- $285.6M
- −$718.9K (−0.3%) vs. Q2 2025
- New holders
- 10
- 39 more added
- Sold out
- 21
- 23 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCYC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 103 | $157.9M |
| Q1 2026 | 98 | $173.6M |
| Q4 2025 | 109 | $276.9M |
| Q3 2025 | 99 | $285.6M |
| Q2 2025 | 110 | $286.3M |
| Q1 2025 | 95 | $354.4M |
| Q4 2024 | 97 | $586.5M |
| Q3 2024 | 105 | $915.3M |
| Q2 2024 | 107 | $804.0M |
| Q1 2024 | 95 | $759.1M |
| Q4 2023 | 101 | $567.4M |
| Q3 2023 | 101 | $651.3M |
| Q2 2023 | 85 | $618.5M |
| Q1 2023 | 89 | $498.9M |
| Q4 2022 | 87 | $695.9M |
| Q3 2022 | 79 | $538.0M |
| Q2 2022 | 82 | $381.1M |
| Q1 2022 | 105 | $884.5M |
| Q4 2021 | 101 | $1.31B |
| Q3 2021 | 69 | $591.1M |
| Q2 2021 | 54 | $376.9M |
| Q1 2021 | 39 | $341.2M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Bicycle Therapeutics PLC; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0 | $0 | 0.00% | −1,041,456−100.0% | Sold out |
| Tybourne Capital Management (HK) Ltd | 0 | $0 | 0.00% | −993,743−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −362,325−100.0% | Sold out |
| AXA S.A. | 0 | $0 | 0.00% | −280,152−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −143,800−100.0% | Sold out |
| Janney Montgomery Scott LLC | 0 | $0 | 0.00% | −100,291−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −52,265−100.0% | Sold out |
| Skandinaviska Enskilda Banken AB (publ) | 0 | $0 | 0.00% | −42,729−100.0% | Sold out |
| Paloma Partners Management Co | 0 | $0 | 0.00% | −39,250−100.0% | Sold out |
| UBS Asset Management Americas Inc | 0 | $0 | 0.00% | −27,300−100.0% | Sold out |
| Ausdal Financial Partners, Inc. | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −1,933−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −1,517−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −1,294−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −1,241−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −923−100.0% | Sold out |
| TD Waterhouse Canada Inc. | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −39−100.0% | Sold out |
| CIBC Private Wealth Group, LLC | 0 | $0 | 0.00% | −23−100.0% | Sold out |